Tarsus Pharmaceuticals Expands Eye Care Pipeline with Alkeus Acquisition
Tarsus Pharmaceuticals strengthens its eye care portfolio by acquiring Alkeus Pharmaceuticals, focusing on gildeuretinol, a potential Stargardt diseas…
Moderna's Groundbreaking mRNA Flu Vaccine Approval: A New Chapter in Vaccination
Moderna's mFLUSIVA, the first FDA-approved mRNA flu vaccine, is set to reshape the vaccination landscape and boost investor confidence.
Trade with the conviction of the 1%.
Institutional-grade market intelligence delivered before the opening bell.
Harrow's Acquisition of TYRVAYA: A Game Changer for Dry Eye Treatment
Harrow Pharmaceuticals acquires TYRVAYA, the first FDA-approved nasal spray for dry eye disease, reshaping the market la…
Moderna's Historic mRNA Influenza Vaccine Approval: What It Means for Investors
Moderna's mFLUSIVA approval marks a pivotal moment for the company and its investors, showcasing its evolution beyond CO…
Bristol-Myers Squibb's Stock Reaction to AstraZeneca Merger Denial Amid Market Surge
Bristol-Myers Squibb's stock dips as AstraZeneca merger talks are denied, contrasting with a bullish Nasdaq 100 surge.
Arrowhead Pharmaceuticals: Strategic Move with FDA Priority Review Voucher
Arrowhead Pharmaceuticals secures FDA Priority Review Voucher for plozasiran, aiming to expedite its supplemental NDA fi…
Eli Lilly's Stellar Earnings and Breakthrough Therapy Status: A Game Changer for Investors
Eli Lilly's earnings beat and FDA milestone could redefine its market trajectory.
Arrowhead Pharmaceuticals' Strategic Acquisition: Priority Review Voucher for Plozasiran
Arrowhead's acquisition of a Priority Review Voucher is set to reshape its market strategy and impact its stock.
Eton Pharmaceuticals Expands Portfolio with ASN-001 Acquisition
Eton Pharmaceuticals enhances its pipeline with the acquisition of ASN-001, targeting the infantile hemangioma market.
Bullish Surge: Nasdaq 100 Signals Market Optimism
The Nasdaq 100's top-10 bullish signal marks a pivotal moment for traders, with tech stocks leading a significant market…
Johnson & Johnson's Robotic Surgery Breakthrough: A Game Changer for Investors
FDA approval of J&J's OTTAVA system sparks optimism, positioning the company as a strong contender in surgical robotics.